Since its beginning 10 years ago, the Innovative Medicines Initiative (IMI) has funded more than 100 projects. At this year’s anniversary, a variety of projects and project partners have been invited to present the results and progression they have made in their projects on October 22-23, 2018.
Benjamin Schmid, research scientist in the Disease Model research group at Bioneer, is joining Peter Reinhardt from AbbVie to present some of the advancements made in the IMI project ADAPTED during day 2 in the talk “An iPSC technology development collaboration – a critical component to enable ADAPTED”.
To learn more about the Disease Modelling research at Bioneer, press here.
More information about the IMI symposium, press here.
- ADAPTED is an abbreviation for Alzheimer’s Disease Apolipoprotein Pathology for Treatment Elucidation and Development project.
- The goal of the project is to ‘Identify new medicines to treat Alzheimer’s Disease through greater understanding of the APOE gene’.
- Start Date: 01/10/2016
- End Date: 30/09/2019
- 13 project partners
- Total budget: EUR 6 796 740
For more information about ADAPTED, press here.